LONDON, May 11 (Reuters Breakingviews) – Drugmakers Novo Nordisk and Eli Lilly are vying for a large slab of the weight loss medications market, which analysts reckon could be worth $100 bln by 2031. In this Viewsroom podcast, Breakingviews columnists discuss how investor optimism in a booming market is unwarranted.
Follow @aimeedonnellan on Twitter
(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.)
Subscribe to Breakingviews’ podcasts, Viewsroom and The Exchange.
Editing by Oliver Taslic
Our Standards: The Thomson Reuters Trust Principles.
Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.